Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VBL grants NanoCarrier Japanese rights to GBM gene therapy

Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111) in Japan for $15 million up front and up to $100 million in milestones,

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE